Peter U Fischer
Overview
Explore the profile of Peter U Fischer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1676
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Montes K, Angoa G, Bjerum C, Guira A, Kouadio O, Ouattara A, et al.
Am J Trop Med Hyg
. 2023 Nov;
110(1):194-198.
PMID: 37956446
Lymphatic filariasis (LF) is a neglected tropical disease that can cause hydrocele and its associated stigma, loss of economic productivity, and depression. Hydrocele surgery is an essential part of LF...
12.
Bjerum C, Koudou B, Ouattara A, Lew D, Goss C, Gabo P, et al.
PLoS Negl Trop Dis
. 2023 Sep;
17(9):e0011633.
PMID: 37721964
Background: Moxidectin is a macrocyclic lactone registered for the treatment of human onchocerciasis. The drug has a good safety profile, large volume of distribution and a long elimination half-life. This...
13.
Chhonker Y, Bjerum C, Bala V, Ouattara A, Koudou B, Gabo T, et al.
PLoS Negl Trop Dis
. 2023 Aug;
17(8):e0011567.
PMID: 37616301
Moxidectin (MOX) is a milbemycin endectocide recently approved by the U.S. FDA for the treatment of onchocerciasis in persons at least 12 years of age. MOX has been shown to...
14.
Di Maggio L, Fischer K, Yates D, Curtis K, Rosa B, Martin J, et al.
Sci Rep
. 2023 Aug;
13(1):13726.
PMID: 37608002
Paragonimiasis is a zoonotic, food-borne trematode infection that affects 21 million people globally. Trematodes interact with their hosts via extracellular vesicles (EV) that carry protein and RNA cargo. We analyzed...
15.
Greene S, Huang Y, Curtis K, King C, Fischer P, Weil G
PLoS Negl Trop Dis
. 2023 Jun;
17(6):e0011364.
PMID: 37285374
Background: Lymphatic filariasis (LF) is a neglected tropical disease and a major cause of chronic disability. Improved diagnostic tests are needed because of long-term persistence of anti-filarial antibodies or circulating...
16.
Opoku N, Doe F, Dubben B, Fetcho N, Fischer K, Fischer P, et al.
PLoS Negl Trop Dis
. 2023 May;
17(5):e0011365.
PMID: 37205721
Background: Onchocerciasis ("river blindness") has been targeted for elimination. New treatments that kill or permanently sterilize female worms could accelerate this process. Prior studies have shown that triple drug treatment...
17.
Eneanya O, Reimer L, Fischer P, Weil G
Int Health
. 2023 Apr;
15(5):566-572.
PMID: 37096453
Background: Lymphatic filariasis (LF) and malaria are important vector-borne diseases that are co-endemic throughout Nigeria. These infections are transmitted by the same mosquito vector species in Nigeria and their transmission...
18.
Fischer K, Dubben B, Debrah L, Kuehlwein J, Ricchiuto A, Debrah A, et al.
Front Med (Lausanne)
. 2023 Feb;
10:1099926.
PMID: 36817770
Background: Novel drugs or drug combinations that kill or permanently sterilize adult worms would be very helpful for treatment and elimination of onchocerciasis. In absence of a reliable biomarker for...
19.
Stolk W, Coffeng L, Bolay F, Eneanya O, Fischer P, Hollingsworth T, et al.
PLoS Negl Trop Dis
. 2022 Dec;
16(12):e0010953.
PMID: 36508458
Background: Mass drug administration (MDA) is the main strategy towards lymphatic filariasis (LF) elimination. Progress is monitored by assessing microfilaraemia (Mf) or circulating filarial antigenaemia (CFA) prevalence, the latter being...
20.
Rosa B, Curtis K, Gilmore P, Martin J, Zhang Q, Sprung R, et al.
Mol Cell Proteomics
. 2022 Nov;
22(1):100454.
PMID: 36435333
Onchocerca volvulus, the causative agent of onchocerciasis, infects over 20 million people and can cause severe dermatitis and ocular conditions including blindness. Current treatments employed in mass drug administration programs...